Science is the foundation upon which we build our innovations, ensuring safety, efficacy and meaningful outcomes.
Recruiting – Click here for more information
A Phase 3, Multicenter, Randomized, Double-Blind, Single-dose Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects with Glenohumeral Osteoarthritis
Recruiting
A Multicenter, Open-label, Randomized, Bupivacaine -Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery
Recruiting – Click here for more information
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera° System in Subjects with Upper Extremity Spasticity
Active/not yet recruiting
A Two-Part, Phase 2, Randomized, Double-blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects with Painful Osteoarthritis of the Knee
Active/not recruiting
An Open-Label, Single Ascending Doe Study to Assess the Safety and Tolerability of FX201 in Patents with Osteoarthritis of the Knee
Recruiting
Innovations in Genicular Outcomes Registry (IGOR) captures prospective observational data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs [NSAIDs]).